Cullinan Therapeutics Inc [CGEM] stock prices are up 5.81% to $7.83 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The CGEM shares have gain 34.08% over the last week, with a monthly amount glided 19.91%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On October 24, 2024, UBS initiated with a Buy rating and assigned a price target of $30 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $40 on May 01, 2024. William Blair initiated its recommendation with a Outperform. Wedbush started tracking with a Outperform rating for this stock on February 15, 2024, and assigned it a price target of $30. In a note dated June 15, 2023, TD Cowen initiated an Outperform rating.
The stock price of Cullinan Therapeutics Inc [CGEM] has been fluctuating between $5.68 and $17.98 over the past year. Currently, Wall Street analysts expect the stock to reach $31.5 within the next 12 months. Cullinan Therapeutics Inc [NASDAQ: CGEM] shares were valued at $7.83 at the most recent close of the market. An investor can expect a potential return of 302.3% based on the average CGEM price forecast.
Analyzing the CGEM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -0.37 and Total Capital is -0.48. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Cullinan Therapeutics Inc [NASDAQ:CGEM]’s Current Ratio is 9.83. On the other hand, the Quick Ratio is 9.83, and the Cash Ratio is 2.6.
Transactions by insiders
Recent insider trading involved Lynx1 Capital Management LP, 10% Owner, that happened on Oct 09 ’25 when 0.63 million shares were purchased. 10% Owner, Lynx1 Capital Management LP completed a deal on Oct 08 ’25 to buy 0.56 million shares. Meanwhile, 10% Owner Lynx1 Capital Management LP bought 0.28 million shares on Oct 10 ’25.
